Two open-label, randomized, parallel-arm studies compared pharmacokinetics, safety, and tolerability of aripiprazole once-monthly 400 mg following deltoid vs gluteal injection in patients with schizophrenia.
A Phase III study of once-monthly Abilify (aripiprazole intramuscular depot formulation) from Otsuka/Lundbeck for the maintenance treatment of Schizophrenia, showed that...
Prevention of relapse is a major challenge in schizophrenia, a disease characterized by poor adherence to antipsychotic medication leading to multiple rehospitalizations and a substantial burden-of-care.
The European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for a once-monthly intramuscular depot formulation of Abilify...
The FDA has approved Aristada (aripiprazole lauroxil), from Alkermes, an extended-release injectable suspension for the treatment of schizophrenia. Aristada is...
Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S announce that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended granting a marketing authorisation in the European Union (EU) for aripiprazole as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole .
Alkermes plc announced positive topline results from a randomized, double-blind, placebo-controlled phase III clinical trial of aripiprazole lauroxil in patients...